hVIVO plc Result of Annual General Meeting (1331G)
24 May 2017 - 11:00PM
UK Regulatory
TIDMHVO
RNS Number : 1331G
hVIVO plc
24 May 2017
For immediate release 2.00pm: 24 May 2017
HVIVO PLC
("hVIVO" or the "Company")
Result of Annual General Meeting
hVIVO plc (AIM: HVO), a specialty biopharma company with
clinical testing capabilities, is pleased to announce that all
resolutions proposed at its Annual General Meeting, held at 10.00am
on 24 May 2017, were duly passed.
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial &
Business Officer)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Michael Burke (Corporate
Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell
(UK) +44 203 727 1000
John Capodanno / Evan Smith (US) +1 212 850 5705
Notes to Editors:
hVIVO plc ("hVIVO"), a specialty biopharma company with
discovery and clinical testing capabilities, is pioneering a
human-based analytical platform to accelerate drug discovery and
development in respiratory and infectious diseases. Leveraging
human disease models in flu, RSV and asthma exacerbation, the hVIVO
platform captures disease in motion, illuminating the entire
disease life cycle from healthy to sick and back to health. Based
in the UK, market leader hVIVO has conducted more than 45 clinical
studies, inoculated over 2000 volunteers and has three
first-in-class therapies currently in development with a growing
pre-clinical pipeline.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMUSSURBUAVUAR
(END) Dow Jones Newswires
May 24, 2017 09:00 ET (13:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2024 to May 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From May 2023 to May 2024